NO20062860L - Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet - Google Patents

Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet

Info

Publication number
NO20062860L
NO20062860L NO20062860A NO20062860A NO20062860L NO 20062860 L NO20062860 L NO 20062860L NO 20062860 A NO20062860 A NO 20062860A NO 20062860 A NO20062860 A NO 20062860A NO 20062860 L NO20062860 L NO 20062860L
Authority
NO
Norway
Prior art keywords
composition
enhancing bioavailability
bioavailability
enhancing
compositions
Prior art date
Application number
NO20062860A
Other languages
English (en)
Inventor
Liang-Chang Dong
Crystal Pollock-Dove
Jasmine Han
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20062860L publication Critical patent/NO20062860L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En foreliggende oppfinnelsen vedrører sammensetninger og fremgangsmåter for økning av den biologiske tilgjengeligheten av fordelaktige midler med vannløselighet.
NO20062860A 2003-11-19 2006-06-19 Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet NO20062860L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52342103P 2003-11-19 2003-11-19
US10/984,401 US20050181049A1 (en) 2003-11-19 2004-11-09 Composition and method for enhancing bioavailability
PCT/US2004/037927 WO2005051358A1 (en) 2003-11-19 2004-11-12 Composition and method for enhancing bioavailability

Publications (1)

Publication Number Publication Date
NO20062860L true NO20062860L (no) 2006-08-17

Family

ID=34636467

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062860A NO20062860L (no) 2003-11-19 2006-06-19 Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet

Country Status (13)

Country Link
US (1) US20050181049A1 (no)
EP (1) EP1684726A4 (no)
JP (1) JP2007511608A (no)
KR (1) KR20060109934A (no)
AR (1) AR048017A1 (no)
AU (1) AU2004292415A1 (no)
CA (1) CA2546618A1 (no)
IL (1) IL175647A0 (no)
MX (1) MXPA06005630A (no)
NO (1) NO20062860L (no)
PE (1) PE20050584A1 (no)
TW (1) TW200529884A (no)
WO (1) WO2005051358A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
KR101129456B1 (ko) * 2004-10-25 2012-03-28 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
EP1817003B1 (en) 2004-10-29 2018-02-21 The Regents of The University of California Porous silicon microparticles for drug delivery to the eye
US20070009589A1 (en) * 2005-07-07 2007-01-11 Kandarapu Raghupathi Extended release compositions
WO2007041079A2 (en) * 2005-09-30 2007-04-12 Alza Corporation Banded controlled release nanoparticle active agent formulation dosage forms and methods
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
PL1954241T3 (pl) * 2005-11-28 2013-03-29 Orexigen Therapeutics Inc Formulacja zonisamidu o przedłużonym uwalnianiu
DK1973529T3 (da) * 2006-01-05 2011-09-12 Veloxis Pharmaceuticals As Fyldbar tablet, som er i stand til at falde hen
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
DE102006054638B4 (de) * 2006-11-16 2014-12-04 Laburnum Gmbh Pharmazeutische Einzeldosisform
US20100210792A1 (en) 2006-12-05 2010-08-19 David Taft Drug delivery
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
GB0709541D0 (en) * 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
FR2918277B1 (fr) * 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
US20100196435A1 (en) 2007-07-10 2010-08-05 The Regents Of The University Of California Materials and methods for delivering compositions to selected tissues
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2135601A1 (en) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices
DK2403482T3 (en) 2009-03-04 2018-03-05 Emplicure Ab ABUSE RESISTANT FORMULATION
EP2427179A4 (en) 2009-05-04 2013-09-11 Psivida Inc POROUS PARTICLES FOR THE RELEASE OF SILICIUM MEDICINES
WO2010128300A1 (en) 2009-05-08 2010-11-11 Aduro Materials Ab Composition for sustained drug delivery comprising geopolymeric binder
EP2440192A4 (en) * 2009-06-11 2013-08-28 Landec Corp COMPOSITIONS AND PROCESSES FOR MATERIAL DELIVERY
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
NZ608598A (en) 2010-09-07 2015-03-27 Orexo Ab A transdermal drug administration device
RU2640918C2 (ru) 2010-11-01 2018-01-12 Псивида Юэс, Инк. Биоразлагаемые устройства на основе кремния для доставки терапевтических агентов
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN105025928A (zh) 2013-03-15 2015-11-04 普西维达公司 用于递送治疗剂的可生物蚀解的硅基组合物
WO2017008059A1 (en) 2015-07-09 2017-01-12 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN117942407A (zh) * 2023-06-13 2024-04-30 复旦大学 提高药物口服生物利用度的载体组合制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2317592A (en) * 1991-07-05 1993-02-11 University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
JP2700141B2 (ja) * 1993-09-17 1998-01-19 富士化学工業株式会社 リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
SE512958C2 (sv) * 1998-04-30 2000-06-12 Triple Crown Ab Kolesterolsänkande komposition innehållande beta-sitosterol och/eller beta-sitostanol samt förfarande för dess framställning
JP4027535B2 (ja) * 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
DE69915346T2 (de) * 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
ES2739852T3 (es) * 2001-07-06 2020-02-04 Veloxis Pharmaceuticals As Aglomeración controlada
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet

Also Published As

Publication number Publication date
WO2005051358A1 (en) 2005-06-09
AR048017A1 (es) 2006-03-22
JP2007511608A (ja) 2007-05-10
EP1684726A4 (en) 2007-10-03
EP1684726A1 (en) 2006-08-02
CA2546618A1 (en) 2005-06-09
IL175647A0 (en) 2006-09-05
AU2004292415A1 (en) 2005-06-09
US20050181049A1 (en) 2005-08-18
WO2005051358A8 (en) 2005-07-21
KR20060109934A (ko) 2006-10-23
MXPA06005630A (es) 2006-12-14
TW200529884A (en) 2005-09-16
PE20050584A1 (es) 2005-08-15

Similar Documents

Publication Publication Date Title
WO2005051358A8 (en) Composition and method for enhancing bioavailability
CO5611137A2 (es) Composiciones de clorhidrato de naltrexona
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
TW200719892A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
BRPI0414599A (pt) pirrol-indóis substituìdos
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
ATE412649T1 (de) Substituierte heteroarylbenzofuransäuren
ZA200705177B (en) Lyophilization of virosomes
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.
DE60329326D1 (de) Tace inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
NO20062699L (no) Smelteblandingsdispergeringer
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
IL173886A0 (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
EP1590666A4 (en) COMPOSITIONS AND METHODS FOR REINFORCED APOPTOSIS
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
EA200701852A1 (ru) Производные аминокислот

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application